The College of Physicians and Surgeons of Nova Scotia rejected Dr. Franklyn Vincent's assertion that a letter he wrote a patient's lawyer revealing "shocking information" about the patient's condition was merely intended to correct inaccuracies.
With an ongoing phase 3 study, pralsetinib seems to be a promising candidate for the treatment of different types of cancer because of the presence of oncogenic rearranged during transfection) fusions.